Examkin

Question

Difficulty: HardHematology and Oncology

During a winter clinical visit, a physician evaluates a patient who reports progressive exhaustion and episodic darkening of her urine over the past three months. The patient also notes that her fingers turn bluish and become painful when she is exposed to chilly morning air. She has no significant past medical history and takes no daily medications. Vital signs are within normal limits. Physical examination reveals conjunctival pallor and mild cervical lymphadenopathy. Laboratory studies show the following:

Hemoglobin: 7.8 g/dL
Mean corpuscular volume: 104 fL
Reticulocyte count: 7.5%
Lactate dehydrogenase: 650 U/L
Haptoglobin: < 10 mg/dL (normal: 41-165 mg/dL)

A direct antiglobulin test is strongly positive for C3 but negative for IgG. A peripheral blood smear demonstrates red blood cell clumping that resolves upon warming the slide.

Which of the following is the most appropriate definitive pharmacologic therapy for this patient's hematologic condition?

  1. RituximabAnswer
  2. B
    Oral prednisone
  3. C
    Splenectomy
  4. D
    Eculizumab
  5. E
    Intravenous immune globulin

Answer

Rituximab is the correct definitive pharmacologic therapy for Cold Agglutinin Disease.
The patient's presentation (acrocyanosis, dark urine in cold weather) and laboratory findings (hemolysis, DAT strongly positive for C3 only, RBC agglutination resolving with heat) are classic for Cold Agglutinin Disease (CAD). CAD is caused by an IgM autoantibody that binds to red blood cells at cold temperatures in the peripheral circulation and fixes complement. As the cells return to the warmer central circulation, the IgM dissociates, but the complement (C3b) remains. This leads to primarily hepatic clearance of the RBCs by Kupffer cells, as well as some intravascular hemolysis. Because the pathogenic clone is B-cell derived, rituximab (an anti-CD20 monoclonal antibody) is the most effective first-line pharmacotherapy for symptomatic patients. Corticosteroids and splenectomy, which are highly effective for warm autoimmune hemolytic anemia, are generally ineffective in CAD.

Step-by-Step Solution

1
Analyze the patient's clinical symptoms and initial laboratory findings.
The patient has signs of active hemolysis (elevated lactate dehydrogenase, low haptoglobin, anemia, reticulocytosis) along with acrocyanosis in cold weather.
To identify the pathophysiologic mechanism causing the anemia.
2
Interpret the direct antiglobulin test (DAT) and peripheral blood smear.
The DAT is positive for C3 and negative for IgG. The smear shows red blood cell agglutination that resolves with warming.
To differentiate between Warm Autoimmune Hemolytic Anemia (IgG+) and Cold Agglutinin Disease (C3+).
3
Establish the precise diagnosis.
The clinical picture and lab results confirm Cold Agglutinin Disease (CAD).
CAD is primarily mediated by IgM antibodies that bind at cold temperatures and fix complement.
4
Select the most appropriate definitive therapy.
Rituximab is selected as the primary pharmacotherapy.
Rituximab targets the CD20-positive B-cell clone producing the pathogenic IgM autoantibodies, whereas standard Warm AIHA treatments like steroids are ineffective.

Key Concept

Cold agglutinin disease is an autoimmune hemolytic anemia mediated by IgM antibodies that fix complement (C3). First-line definitive pharmacologic treatment is rituximab, as corticosteroids and splenectomy are largely ineffective due to the hepatic clearance of complement-opsonized cells.
Rate this question

Topics

Hematology and Oncology

More questions from this topic